Key result
Titanium-nitride-oxide-coated bioactive stents show similar stent-oriented outcomes to everolimus-eluting stents at 24 months.
Why the study?
The BASE-ACS trial previously demonstrated non-inferiority of titanium-nitride-oxide-coated bioactive stents compared to everolimus-eluting stents at 12 months in ACS patients, but longer-term stent-oriented versus patient-oriented outcomes were not reported.
Do titanium-nitride-oxide-coated bioactive stents improve stent-oriented or patient-oriented outcomes compared to everolimus-eluting stents in patients undergoing early percutaneous coronary intervention for acute coronary syndrome?
RCT (n=827)
Do titanium-nitride-oxide-coated bioactive stents improve stent-oriented or patient-oriented outcomes compared to everolimus-eluting stents in patients undergoing early percutaneous coronary intervention for acute coronary syndrome?
Absolute Event Rate: 10.1% vs 11.2%
p-value: p=0.53
In patients with ACS undergoing early PCI, titanium-nitride-oxide-coated bioactive stents showed similar 2-year stent-oriented and patient-oriented outcomes compared to everolimus-eluting stents.
Similar 24-month stent- and patient-oriented outcomes with BAS versus EES; extends 12-month non-inferiority data but leaves open long-term adoption.
BACKGROUND: The BASE-ACS trial demonstrated an outcome of the titanium-nitride-oxide-coated bioactive stents (BAS) statistically non-inferior to that of the everolimus-eluting stents (EES) at 12-month follow-up in patients presenting with acute coronary syndrome (ACS). We performed a post hoc analysis of the BASE-ACS trial with particular focus on stent-oriented versus patient-oriented outcome at 24-month follow-up. METHODS: A total of 827 patients with ACS were randomly assigned to receive either BAS (417) or EES (410). Stent-oriented outcome was defined as a composite of cardiac death, target vessel-related non-fatal myocardial infarction, or ischemia-driven target lesion revascularization. Patient-oriented outcome was defined as a composite of all-cause death, any non-fatal myocardial infarction, or any revascularization. RESULTS: Clinical follow-up for 24 months was completed in 406 (97.4%) patients in the BAS group and in 398 (97.1%) in the EES group. Stent-oriented outcome at 24-month follow-up occurred at similar frequencies in the two stent groups (10.1% for BAS versus 11.2% for EES, P=0.53). Likewise, patient-oriented outcome at 24-month follow-up was similar in the two groups (16.3% versus 19.8%, respectively, P=0.2). CONCLUSIONS: In patients presenting with ACS, the rates of both stent-oriented and patient-oriented outcomes at 24-month follow-up in the BAS group were similar to those in the EES group.
No takes yet. Share an insight, caveat, or question.
Romppanen et al. (2013) conducted an RCT in Acute coronary syndrome (n=827). Titanium-nitride-oxide-coated bioactive stents (BAS) vs. Everolimus-eluting stents (EES) was evaluated on Stent-oriented outcome (composite of cardiac death, target vessel-related non-fatal myocardial infarction, or ischemia-driven target lesion revascularization) (p=0.53). Titanium-nitride-oxide-coated bioactive stents resulted in similar rates of stent-oriented outcomes compared to everolimus-eluting stents at 24 months (10.1% vs 11.2%, P=0.53).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: